Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Choosing a total market fund for a Roth IRA doesn't have to be hard. Compare options, fees, and diversification to build a solid retirement strategy.
28,468 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A first-look at Vaalco Energy 2026 earnings, what Q1 results might reveal about production, cash flow, and risk. Lear...
SanDisk is leading a powerful memory-chip rally, jumping 558% this year as AI-driven data-center demand reshapes expe...
A 67-year-old single retiree with $920,000 could extend retirement beyond typical horizons if Social Security COLA re...
Markets react to renewed talks on extending an Iran ceasefire, with potential sanctions relief and Oil-flow changes o...
In a shifting rate environment, investors weigh after-tax returns. Some Schwab analysts argue that municipal bonds be...
Realtracs will extend its Zillow data feed through June 8 while ongoing licensing talks address broker compensation a...
Cardano is at a pivotal juncture as social chatter and on-chain activity surge while ADA trades near multi-year lows,...
SBI Shinsei Bank launches a three-month crypto deposit reward campaign, offering 20% of interest as vouchers redeemab...
Despite a chorus of buy ratings on Shopify, a dissenting view flags limited upside as AI tools and monetization effor...
An AI-driven forecast linked to Sam Altman points to a sharp Bitcoin rally by year-end 2026, with specific price band...
Treasury Secretary Scott Bessent pitched a bold growth plan: 3% GDP growth without higher inflation, anchored by AI-d...